Education

Watch “The FDA's Role in Gene Therapy,” from ASGCT and NORD

ASGCT Staff - November 15, 2019

The webinars in this series are designed to inform patients, patient advocates, families, and the public about various aspects of gene therapy.

The third in a series of five educational webinars from ASGCT and the National Organization for Rare Disorders (NORD), is now available to watch for free.

 

Download the Slides Here

This session, held on Oct. 30, explores regulatory pathways for gene therapies, how gene therapies are deemed safe, and more. Speakers include Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER); and Julie Tierney, J.D., senior policy advisory for strategic planning and legislation at CBER. To learn more about the FDA's role in the process of developing gene therapies, visit our Patient Education portal.

Mark your calendar for the rest of the sessions in this free webinar series. All the webinars are designed to inform patients, patient advocates, families, and the public about various aspects of gene therapy.

  • Understanding the Gene Therapy Process and Aftercare – Wednesday, November 20
  • Life After Gene Therapy – Wednesday, December 18

If you missed the first two webinars, you can watch “Gene Therapy: Yesterday, Today and Tomorrow” here, and "The Science Behind Gene Therapy" here

Share This Page

Related Articles

Education

ASGCT, NORD Partner for CME Program

ASGCT Staff - April 19, 2021
Education

Learn How mRNA Vaccines Offer Protection from COVID-19

ASGCT Staff - December 30, 2020
Education

Understanding Ethical Concerns About Germline Gene Editing

ASGCT Staff - December 16, 2020
Education

Viewing Breast Cancer with a CRISPR Lens: The Potential of Gene-Editing Treatment

Eoghan J. Mulholland, Ph.D. - October 20, 2020